Mannatech
Direct seller of Ambrotose-centered nutritional supplements and personal-care products.
Something off on this page? Send us feedback.
Profile
Develops and markets proprietary nutritional supplements, skin-care, weight-management, and fitness products through a global network of independent associates and preferred customers. Most revenue is derived from product sales, while access to mainland China relies on cross-border e-commerce rather than licensed direct selling.
Sells proprietary nutritional supplements, skin-care, weight-management, and fitness products, centered on its Ambrotose glyconutrient line, through independent associates and preferred customers in 25 markets. Product sales, associate fees, subscription tools, and training or event fees make up its revenue streams; several Ambrotose and TruHealth products supply a significant share of sales.
Operates mainly through network marketing across the Americas, Asia/Pacific, Europe, the Middle East, and Africa, with South Korea its largest market. Mainland China is served through cross-border e-commerce because the company lacks a Chinese direct-selling license. All products are manufactured by third parties, and arabinogalactan for Ambrotose has no identified alternative supplier. Dietary-supplement and direct-selling rules, including associate health and income claims, shape the operating model.
Company facts
Key statistics
Year to date −15.3% · Average volume (30d) 10.6K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | — | $0.53 | — | — | $26.7M | — | +1.60% |
| Aug 11, 2026Q2 FY26 | — | $0.53 | — | — | $26.7M | — | +1.60% |
| May 14, 2026Q1 FY26 | — | $0.49 | — | — | $24.9M | — | −8.66% |
| Apr 15, 2026Q1 FY26 | — | −$5.94 | — | — | $26.6M | — | +6.85% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $26.6M | $25.7M | $29.2M | $26.6M | $24.9M | $26.7M | |
| Gross profit | $19.7M | $18.9M | $22.3M | $20.1M | $18.9M | $20.5M | |
| Operating income | −$833.0K | −$1.4M | $2.0M | −$157.0K | −$180.0K | $998.0K | |
| Net income | −$1.5M | −$4.3M | $1.9M | −$11.3M | $950.0K | $1.0M | |
| Diluted EPS | −$0.80 | −$2.27 | $1.01 | −$5.94 | $0.49 | $0.53 | |
| Gross margin | 74.3% | 73.6% | 76.4% | 75.3% | 75.7% | 76.9% | |
| Operating margin | -3.1% | -5.6% | 6.9% | -0.6% | -0.7% | 3.7% |
Fiscal years (4-quarter sums)FY21 $159.8M · FY22 $137.2M · FY23 $132.0M · FY24 $117.9M · FY25 $108.0M
Revenue by product · FY24
Revenue by geography · FY24
Balance sheet, Jun 30, 2026Cash & short-term investments $6.0M · Total debt $8.5M · Total assets $27.5M · Shareholders' equity −$5.0M
Dividends
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 14, 2023 | Jun 15 | Jun 29 | $0.20 | |
| Mar 15, 2023 | Mar 16 | Mar 30 | $0.20 | |
| Dec 13, 2022 | Dec 14 | Dec 28 | $0.20 | |
| Sep 13, 2022 | Sep 14 | Sep 28 | $0.20 | |
| Jun 14, 2022 | Jun 15 | Jun 29 | $0.20 | |
| Mar 15, 2022 | Mar 16 | Mar 30 | $0.20 | |
| Dec 14, 2021 | Dec 15 | Dec 29 | $1.70 | special dividend |
| Sep 14, 2021 | Sep 15 | Sep 29 | $0.20 |
Ownership
Shares outstanding 1.93M · Float 937.9K · 48.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| J. Stanley Fredrick · director | 361.8K | 18.75% | Form 4 | Jan 6, 2026 |
| Tyler Rameson · director | 306.7K | 15.89% | Form 4 | Jan 6, 2026 |
| Lacore Terry | 100.0K | 5.30% | 13G | Jan 24, 2025 |
| Toth Robert | 99.3K | 5.10% | 13D | Apr 24, 2026 |
| Marlin Ray Robbins | 96.4K | 5.10% | 13G | Nov 1, 2024 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Larry A. Jobe | director | +2,803 | $4.12 |
| May 19, 2026 | Kevin Andrew Robbins | director | +7,100 | $4.17 |
| May 19, 2026 | Larry A. Jobe | director | +5,000 | $4.20 |
Peers
- Herbalife
Broad wellness and distributor-recruitment rival.
- Nu Skin
Wellness and beauty rival with a global affiliate network.
- USANA Health Sciences
Supplement, personal-care, and distributor-network rival.
- Nature's Sunshine Products
Nutrition and field-sales rival, including Synergy Worldwide.
- LifeVantage
Direct-selling wellness and beauty rival with independent consultants.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mannatech | $7.11 | +0.57% | $13.0M | — | — | 0.1 | +3.8% |
| Herbalife | $12.50 | +0.52% | $1.29B | 8.0 | 4.7 | 0.2 | +5.4% |
| Nu Skin | $4.85 | +0.21% | $235.5M | — | 5.0 | 0.2 | −17.1% |
| USANA Health Sciences | $14.04 | +0.07% | $259.2M | — | 13.8 | 0.3 | −5.3% |
| Nature's Sunshine Products | $14.21 | −0.07% | $249.9M | 14.1 | 13.2 | 0.5 | +2.0% |
| LifeVantage | $6.26 | −1.11% | $80.2M | 15.9 | 17.3 | 0.4 | −23.1% |
| Median | 14.1 | 13.2 | 0.3 | −5.3% |